RANI
Rani Therapeutics Holdings, Inc.Company with tickers: RANI
Press releases and events scraped from the company's investor relations website. News and event listings link back to the original source.
Recent news
| Date | Headline |
|---|---|
| 2026-05-26 |
Rani Therapeutics Holdings, Inc. Announces Pricing of $20.0 Million Registered Direct Offering of Class A Common Stock Priced At-The-Market Under Nasdaq Rules
SAN JOSE, Calif., May 26, 2026 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today announced that it has entered into a securities purchase agreement |
| 2026-05-15 |
Rani Therapeutics Reports First Quarter 2026 Financial Results; Provides Corporate Update; Announces CFO Transition
- Continued advancement of the ongoing Phase 1 study of RT-114 via RaniPill® for the treatment of obesity in collaboration with ProGen – - Appointed Alireza Javadi, Ph.D. as Chief Technical Officer - - Appointed Jesper Høiland as Head of Strategy and Dr. |
| 2026-05-12 |
Rani Therapeutics to Participate in the H.C. Wainwright Annual BioConnect Investor Conference
SAN JOSE, Calif., May 12, 2026 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today announced that the company’s management team will participate in |
| 2026-04-09 |
Rani Therapeutics Appoints Dr. Sara Kenkare-Mitra as Strategic Advisor to Advance Platform and Clinical Strategy
SAN JOSE, Calif., April 09, 2026 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today announced the appointment of Dr. |
| 2026-03-26 |
Rani Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results; Provides Corporate Update
- Announced up to $1.085 billion collaboration with Chugai Pharmaceutical Co. for multiple high-value therapeutics and completed $60.3 million oversubscribed private placement led by Samsara BioCapital with participation from RA Capital Management, Special Situations Funds, and Invus – - Announced |
| 2026-03-25 |
Rani Therapeutics Appoints Jesper Høiland as Head of Strategy to Advance Corporate and Pipeline Prioritization
SAN JOSE, Calif., March 25, 2026 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today announced the appointment of Jesper Høiland as Head of Strategy. |
| 2026-03-19 |
Rani Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results
SAN JOSE, Calif., March 19, 2026 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today announced that it plans to release financial results for the |
| 2026-01-28 |
Rani Therapeutics Announces the Promotion of Alireza Javadi, Ph.D. to Chief Technical Officer
SAN JOSE, Calif., Jan. 28, 2026 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today announced the promotion of Alireza Javadi, Ph.D., to Chief |
| 2026-01-08 |
Rani Therapeutics Initiates Phase 1 Study of RT-114 RaniPill® for the Treatment of Obesity in Collaboration with ProGen
- A phase 1 study to evaluate safety, tolerability, bioavailability, pharmacokinetics, and weight loss of GLP-1/GLP-2 dual agonist, PG-102, administered orally via RaniPill ® capsule versus subcutaneous injection - SAN JOSE, Calif., Jan. 08, 2026 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, |
| 2025-11-24 |
Rani Therapeutics to Participate in the Evercore Healthcare Conference
SAN JOSE, Calif., Nov. 24, 2025 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today announced that the company’s management team will participate in |
Past events
| Date | Event | Type |
|---|---|---|
| 2026-03-26 | Rani Therapeutics Fourth Quarter and Full Year 2025 Financial Results Conference Call | Conference |
| 2025-12-03 | 8th Annual Evercore Healthcare Conference | Conference |
| 2025-03-31 | Rani Therapeutics Fourth Quarter and Full Year 2024 Financial Results Conference Call | Conference |
| 2024-12-04 | 7th Annual Evercore ISI HealthCONx Conference | Conference |
| 2024-11-18 | Stifel Healthcare Conference | Conference |
| 2024-11-14 | UBS Global Healthcare Conference | Conference |
| 2024-09-18 | 2024 Cantor Global Healthcare Conference | Conference |
| 2024-09-10 | H.C. Wainwright 26th Annual Global Investment Conference | Conference |
| 2024-08-13 | Canaccord Genuity 44th Annual Growth Conference | Conference |
| 2024-06-24 | Rani Therapeutics and ProGen Collaboration Conference Call | Conference |
Source: https://ir.ranitherapeutics.com/